1. Home
  2. PHVS vs UTL Comparison

PHVS vs UTL Comparison

Compare PHVS & UTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHVS
  • UTL
  • Stock Information
  • Founded
  • PHVS 2015
  • UTL 1984
  • Country
  • PHVS Switzerland
  • UTL United States
  • Employees
  • PHVS N/A
  • UTL N/A
  • Industry
  • PHVS Biotechnology: Pharmaceutical Preparations
  • UTL Power Generation
  • Sector
  • PHVS Health Care
  • UTL Utilities
  • Exchange
  • PHVS Nasdaq
  • UTL Nasdaq
  • Market Cap
  • PHVS 980.9M
  • UTL 842.0M
  • IPO Year
  • PHVS 2021
  • UTL N/A
  • Fundamental
  • Price
  • PHVS $22.32
  • UTL $51.52
  • Analyst Decision
  • PHVS Buy
  • UTL Hold
  • Analyst Count
  • PHVS 6
  • UTL 1
  • Target Price
  • PHVS $37.17
  • UTL $55.00
  • AVG Volume (30 Days)
  • PHVS 33.8K
  • UTL 73.7K
  • Earning Date
  • PHVS 08-13-2025
  • UTL 08-05-2025
  • Dividend Yield
  • PHVS N/A
  • UTL 3.47%
  • EPS Growth
  • PHVS N/A
  • UTL N/A
  • EPS
  • PHVS N/A
  • UTL 2.93
  • Revenue
  • PHVS N/A
  • UTL $486,900,000.00
  • Revenue This Year
  • PHVS N/A
  • UTL $16.37
  • Revenue Next Year
  • PHVS N/A
  • UTL $5.20
  • P/E Ratio
  • PHVS N/A
  • UTL $17.50
  • Revenue Growth
  • PHVS N/A
  • UTL N/A
  • 52 Week Low
  • PHVS $11.51
  • UTL $51.10
  • 52 Week High
  • PHVS $25.76
  • UTL $63.52
  • Technical
  • Relative Strength Index (RSI)
  • PHVS 73.31
  • UTL 39.34
  • Support Level
  • PHVS $17.63
  • UTL $51.12
  • Resistance Level
  • PHVS $19.00
  • UTL $52.25
  • Average True Range (ATR)
  • PHVS 1.20
  • UTL 1.01
  • MACD
  • PHVS 0.35
  • UTL 0.04
  • Stochastic Oscillator
  • PHVS 92.15
  • UTL 9.46

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

About UTL UNITIL Corporation

Unitil Corp is a holding company, through its subsidiaries it is engaged in the local distribution of electricity and natural gas throughout its service territories in the states of New Hampshire, Massachusetts, and Maine. The Company has two operating and reportable segments: Utility Electric Operations and Utility Gas Operations. Majority of revenue is gained from Electric Segment.

Share on Social Networks: